Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06180876
Other study ID # XJH-A-20220628
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 25, 2022
Est. completion date January 30, 2024

Study information

Verified date December 2023
Source Air Force Military Medical University, China
Contact Zhihong Lu
Phone +8613891975018
Email deerlu23@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Remimazolam is a novel benzodiazepine with ultra-short onset and offset of its effect. It can be used for general anesthesia. However, classical benzodiazepine such as midazolam was reported to increase the risk of postoperative delirium. Thus, the investigators aim to investigate the effect of remimazolam general anesthesia on postoperative delirium in elderly patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 190
Est. completion date January 30, 2024
Est. primary completion date January 25, 2024
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria: - Age =65 years - patients scheduled for elective surgery under general anesthesia Exclusion Criteria: - American Society of Anesthesiologists status =? - history of neurologic or psychiatric diseases - difficulty in communication - abuse of drug or alcohol - suspected allergy to propofol or benzodiazepines

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
remimazolam
continuous infusion
propofol
continuous infusion

Locations

Country Name City State
China Xijing hospital, Fourth military medical university Xi'an Shaanxi

Sponsors (1)

Lead Sponsor Collaborator
Zhihong LU

Country where clinical trial is conducted

China, 

References & Publications (5)

Doi M, Morita K, Takeda J, Sakamoto A, Yamakage M, Suzuki T. Efficacy and safety of remimazolam versus propofol for general anesthesia: a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial. J Anesth. 2020 Aug;34(4):543-553. doi: 10.1007/s00540-020-02788-6. Epub 2020 May 16. — View Citation

Kilpatrick GJ. Remimazolam: Non-Clinical and Clinical Profile of a New Sedative/Anesthetic Agent. Front Pharmacol. 2021 Jul 20;12:690875. doi: 10.3389/fphar.2021.690875. eCollection 2021. — View Citation

Liu T, Lai T, Chen J, Lu Y, He F, Chen Y, Xie Y. Effect of remimazolam induction on hemodynamics in patients undergoing valve replacement surgery: A randomized, double-blind, controlled trial. Pharmacol Res Perspect. 2021 Oct;9(5):e00851. doi: 10.1002/prp2.851. — View Citation

Oka S, Satomi H, Sekino R, Taguchi K, Kajiwara M, Oi Y, Kobayashi R. Sedation outcomes for remimazolam, a new benzodiazepine. J Oral Sci. 2021 Jun 29;63(3):209-211. doi: 10.2334/josnusd.21-0051. Epub 2021 Jun 7. — View Citation

Tang F, Yi JM, Gong HY, Lu ZY, Chen J, Fang B, Chen C, Liu ZY. Remimazolam benzenesulfonate anesthesia effectiveness in cardiac surgery patients under general anesthesia. World J Clin Cases. 2021 Dec 6;9(34):10595-10603. doi: 10.12998/wjcc.v9.i34.10595. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary incidence of delirium by 3 days after surgery from end of surgery to 3 days after surgery, in a total of 3 days
Secondary incidence of delirium by 30 minutes after extubation from extubation of tracheal tube to 30 minutes after extubation, in a total of 30 minutes
Secondary incidence of delirium by 1 day after surgery from end of surgery to 1 day after surgery, in a total of 1 day
Secondary incidence of in-hospital delirium after surgery from end of surgery to discharge from hospital, in an average of 5 days
Secondary time to awake from end of surgery to response to verbal command, in an average of 10 minutes
Secondary incidence of hypotension during surgery hypotension is defined as systolic blood pressure decreasing by more than 20% of baseline value from start of anesthesia induction to extubation, in an average of 2 hours
Secondary incidence of hypertension during surgery hypertension is defined as systolic blood pressure increasing by more than 20% of baseline value from start of anesthesia induction to extubation, in an average of 2 hours
Secondary level of tumor necrosis factor a at the end of the surgery at the end of the surgery
Secondary level of serum S100ß at the end of the surgery at the end of the surgery
Secondary level of interleukin a at the end of the surgery at the end of the surgery
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03210077 - Romanian Entropy Clinical Study Network
Completed NCT04851574 - PKPD of Rocuronium and Sugammadex Profile in Pediatric Patients
Recruiting NCT03705728 - Automated Administration of Intravenous Compared With Inhalatory Anesthesia on the Occurrence of Postoperative Delirium N/A
Recruiting NCT02213718 - The Effect of Desflurane on Myocardial Function in Patients Undergoing Coronary Artery Bypass Grafting Phase 4
Completed NCT05468671 - Clinical Application Value of Remazolam Combined With Sugammadex Sodium in Anesthesia for Endotracheal Surgery Under Bronchoscopy Phase 4
Recruiting NCT06216002 - Incidence of Residual Neuromuscular Blockade in Fraility in OncoGynae Surgery N/A
Recruiting NCT05208502 - Observational of Emergence Time Between Patients Receive General Anesthesia With BIS or Spectrogram EEG Monitor
Completed NCT02617680 - Factors Affecting the Effective End-tidal Concentration of Desflurane Anaesthesia N/A
Recruiting NCT05935930 - Postoperative Effects of Propofol Versus Sevoflurane Anesthesia Phase 4